Emerging Biomarkers for Neoadjuvant Immune Checkpoint Inhibitors in Operable Non–Small Cell Lung Cancer
This article summarizes the initial results from the trials of neoadjuvant immune checkpoint inhibitors in patients with early-stage and locally advanced operable NSCLC and review the findings of studies investigating emerging biomarkers associated with those trials.
Advertisement
News & Literature Highlights